{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"For participants who demonstrated a confirmed Complete Response (CR) or partial response (PR), DOR was defined as the time from CR or PR to documented disease progression or death. CR and PR were assessed according to the International Working Group (IWG) response criteria in myelodysplasia per Cheson et al. 2006. CR was demonstrated by ≤5% myeloblasts with normal maturation of all cell lines in the bone marrow (persistent dysplasia will be noted) and normal findings for hemoglobin, platelet count, neutrophil count, and absence of blasts in the blood. PR was all CR criteria if abnormal before treatment except bone marrow blasts decreased by ≥50% over pre-treatment but still \\>5%. Cellularity and morphology are not relevant. DOR as assessed by the investigator is presented.","groups":[{"description":"Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Cohort 1: Myelodysplastic Syndrome (MDS)"}],"populationDescription":"All participants in Cohort 1 with a baseline efficacy evaluation, at least 1 post-baseline efficacy evaluation, and who demonstrated a PR or CR. DOR was not analyzed because there were no participants who demonstrated a PR or CR in Cohort 1.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Duration of Response (DOR) in Cohort 1: Myelodysplastic Syndrome (MDS)","type":"SECONDARY"}